Physician profile
Ruby Chahal
NPI 1205148111
$819.91
in general payments reported to CMS, 2019-2025
14 companies · $65.53 in 2025
The $65.53 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.55 · 2020: $44.96 · 2021: $46.58 · 2022: $105 · 2023: $132 · 2024: $384 · 2025: $65.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $153.08 | 2020-2024 | Collagenase Santyl |
| Integra Lifesciences Corporation | $130.98 | 2020-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Organogenesis INC. | $130.84 | 2022-2024 | Puraply Am |
| Kerecis Limited | $105.09 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Treace Medical Concepts, INC. | $74.17 | 2022-2025 | |
| Davol INC. | $43.53 | 2024 | Arista Ah Flexitip |
| Polynovo North America LLC | $32.41 | 2025 | Novosorb Btm |
| Melinta Therapeutics, LLC | $30.65 | 2019 | |
| Abbvie INC. | $28.37 | 2023 | Teflaro |
| Ethicon US, LLC | $21.46 | 2022 | |
| Paragon 28, INC. | $20.13 | 2023 | Mtp |
| Zimmer Biomet Holdings, INC. | $19.45 | 2024 | Nextremity General Instrument |
| Averitas Pharma INC. | $17.85 | 2024 | Qutenza |
| Merck Sharp & Dohme LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Chahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.